NYSE:INSP

Inspire Medical Systems Competitors

$218.45
+7.27 (+3.44 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$210.68
Now: $218.45
$218.71
50-Day Range
$186.77
MA: $213.32
$249.25
52-Week Range
$61.04
Now: $218.45
$252.25
Volume167,037 shs
Average Volume237,441 shs
Market Capitalization$5.93 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.71

Competitors

Inspire Medical Systems (NYSE:INSP) Vs. TFX, PODD, ABMD, NVCR, PEN, and HRC

Should you be buying INSP stock or one of its competitors? Companies in the industry of "surgical & medical instruments" are considered alternatives and competitors to Inspire Medical Systems, including Teleflex (TFX), Insulet (PODD), Abiomed (ABMD), NovoCure (NVCR), Penumbra (PEN), and Hill-Rom (HRC).

Teleflex (NYSE:TFX) and Inspire Medical Systems (NYSE:INSP) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends and risk.

Insider & Institutional Ownership

89.8% of Teleflex shares are held by institutional investors. Comparatively, 96.3% of Inspire Medical Systems shares are held by institutional investors. 2.2% of Teleflex shares are held by company insiders. Comparatively, 6.6% of Inspire Medical Systems shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Teleflex and Inspire Medical Systems' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Teleflex$2.60 billion7.69$461.47 million$11.1538.30
Inspire Medical Systems$82.05 million72.33$-33,240,000.00($1.40)-156.04

Teleflex has higher revenue and earnings than Inspire Medical Systems. Inspire Medical Systems is trading at a lower price-to-earnings ratio than Teleflex, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Teleflex has a beta of 1.14, meaning that its share price is 14% more volatile than the S&P 500. Comparatively, Inspire Medical Systems has a beta of 1.71, meaning that its share price is 71% more volatile than the S&P 500.

Profitability

This table compares Teleflex and Inspire Medical Systems' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Teleflex14.66%16.33%7.66%
Inspire Medical Systems-61.07%-32.23%-26.42%

Analyst Recommendations

This is a breakdown of recent recommendations for Teleflex and Inspire Medical Systems, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Teleflex00813.11
Inspire Medical Systems03802.73

Teleflex currently has a consensus target price of $453.4444, indicating a potential upside of 6.17%. Inspire Medical Systems has a consensus target price of $168.5455, indicating a potential downside of 22.84%. Given Teleflex's stronger consensus rating and higher possible upside, equities research analysts plainly believe Teleflex is more favorable than Inspire Medical Systems.

Summary

Teleflex beats Inspire Medical Systems on 10 of the 14 factors compared between the two stocks.

Insulet (NASDAQ:PODD) and Inspire Medical Systems (NYSE:INSP) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, earnings, dividends, analyst recommendations, institutional ownership, risk and valuation.

Institutional & Insider Ownership

96.3% of Inspire Medical Systems shares are held by institutional investors. 1.1% of Insulet shares are held by insiders. Comparatively, 6.6% of Inspire Medical Systems shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Volatility and Risk

Insulet has a beta of 0.76, suggesting that its share price is 24% less volatile than the S&P 500. Comparatively, Inspire Medical Systems has a beta of 1.71, suggesting that its share price is 71% more volatile than the S&P 500.

Earnings & Valuation

This table compares Insulet and Inspire Medical Systems' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Insulet$738.20 million25.70$11.60 million$0.191,511.21
Inspire Medical Systems$82.05 million72.33$-33,240,000.00($1.40)-156.04

Insulet has higher revenue and earnings than Inspire Medical Systems. Inspire Medical Systems is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Insulet and Inspire Medical Systems' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Insulet3.33%8.94%2.07%
Inspire Medical Systems-61.07%-32.23%-26.42%

Analyst Recommendations

This is a breakdown of current ratings and price targets for Insulet and Inspire Medical Systems, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Insulet19702.35
Inspire Medical Systems03802.73

Insulet currently has a consensus price target of $254.2353, suggesting a potential downside of 11.46%. Inspire Medical Systems has a consensus price target of $168.5455, suggesting a potential downside of 22.84%. Given Insulet's higher probable upside, equities analysts clearly believe Insulet is more favorable than Inspire Medical Systems.

Summary

Insulet beats Inspire Medical Systems on 8 of the 14 factors compared between the two stocks.

Abiomed (NASDAQ:ABMD) and Inspire Medical Systems (NYSE:INSP) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, earnings, dividends and risk.

Earnings and Valuation

This table compares Abiomed and Inspire Medical Systems' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Abiomed$840.88 million17.96$203.01 million$4.7470.42
Inspire Medical Systems$82.05 million72.33$-33,240,000.00($1.40)-156.04

Abiomed has higher revenue and earnings than Inspire Medical Systems. Inspire Medical Systems is trading at a lower price-to-earnings ratio than Abiomed, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and target prices for Abiomed and Inspire Medical Systems, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Abiomed12202.20
Inspire Medical Systems03802.73

Abiomed currently has a consensus price target of $348.3333, indicating a potential upside of 4.35%. Inspire Medical Systems has a consensus price target of $168.5455, indicating a potential downside of 22.84%. Given Abiomed's higher possible upside, research analysts plainly believe Abiomed is more favorable than Inspire Medical Systems.

Insider and Institutional Ownership

94.0% of Abiomed shares are owned by institutional investors. Comparatively, 96.3% of Inspire Medical Systems shares are owned by institutional investors. 3.4% of Abiomed shares are owned by company insiders. Comparatively, 6.6% of Inspire Medical Systems shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Volatility & Risk

Abiomed has a beta of 1.41, indicating that its share price is 41% more volatile than the S&P 500. Comparatively, Inspire Medical Systems has a beta of 1.71, indicating that its share price is 71% more volatile than the S&P 500.

Profitability

This table compares Abiomed and Inspire Medical Systems' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Abiomed25.89%15.34%13.51%
Inspire Medical Systems-61.07%-32.23%-26.42%

Summary

Abiomed beats Inspire Medical Systems on 8 of the 14 factors compared between the two stocks.

Inspire Medical Systems (NYSE:INSP) and NovoCure (NASDAQ:NVCR) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, earnings, profitability, institutional ownership, valuation and analyst recommendations.

Valuation and Earnings

This table compares Inspire Medical Systems and NovoCure's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Inspire Medical Systems$82.05 million72.33$-33,240,000.00($1.40)-156.04
NovoCure$351.32 million38.51$-7,230,000.00($0.07)-1,887.00

NovoCure has higher revenue and earnings than Inspire Medical Systems. NovoCure is trading at a lower price-to-earnings ratio than Inspire Medical Systems, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Inspire Medical Systems and NovoCure's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Inspire Medical Systems-61.07%-32.23%-26.42%
NovoCure4.26%7.40%3.94%

Volatility and Risk

Inspire Medical Systems has a beta of 1.71, meaning that its stock price is 71% more volatile than the S&P 500. Comparatively, NovoCure has a beta of 1.29, meaning that its stock price is 29% more volatile than the S&P 500.

Institutional and Insider Ownership

96.3% of Inspire Medical Systems shares are held by institutional investors. Comparatively, 71.1% of NovoCure shares are held by institutional investors. 6.6% of Inspire Medical Systems shares are held by company insiders. Comparatively, 5.1% of NovoCure shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of current recommendations and price targets for Inspire Medical Systems and NovoCure, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Inspire Medical Systems03802.73
NovoCure14402.33

Inspire Medical Systems currently has a consensus price target of $168.5455, indicating a potential downside of 22.84%. NovoCure has a consensus price target of $139.2857, indicating a potential upside of 5.45%. Given NovoCure's higher probable upside, analysts plainly believe NovoCure is more favorable than Inspire Medical Systems.

Summary

NovoCure beats Inspire Medical Systems on 8 of the 14 factors compared between the two stocks.

Penumbra (NYSE:PEN) and Inspire Medical Systems (NYSE:INSP) are both mid-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, dividends, institutional ownership, profitability, analyst recommendations, earnings and risk.

Analyst Recommendations

This is a summary of current recommendations and price targets for Penumbra and Inspire Medical Systems, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Penumbra02402.67
Inspire Medical Systems03802.73

Penumbra currently has a consensus price target of $279.00, indicating a potential upside of 2.56%. Inspire Medical Systems has a consensus price target of $168.5455, indicating a potential downside of 22.84%. Given Penumbra's higher probable upside, analysts plainly believe Penumbra is more favorable than Inspire Medical Systems.

Profitability

This table compares Penumbra and Inspire Medical Systems' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Penumbra-1.79%-0.12%-0.09%
Inspire Medical Systems-61.07%-32.23%-26.42%

Volatility & Risk

Penumbra has a beta of 0.43, suggesting that its stock price is 57% less volatile than the S&P 500. Comparatively, Inspire Medical Systems has a beta of 1.71, suggesting that its stock price is 71% more volatile than the S&P 500.

Insider & Institutional Ownership

88.2% of Penumbra shares are held by institutional investors. Comparatively, 96.3% of Inspire Medical Systems shares are held by institutional investors. 8.9% of Penumbra shares are held by insiders. Comparatively, 6.6% of Inspire Medical Systems shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Penumbra and Inspire Medical Systems' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Penumbra$547.41 million18.11$48.46 million$0.98277.58
Inspire Medical Systems$82.05 million72.33$-33,240,000.00($1.40)-156.04

Penumbra has higher revenue and earnings than Inspire Medical Systems. Inspire Medical Systems is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks.

Summary

Penumbra beats Inspire Medical Systems on 8 of the 14 factors compared between the two stocks.

Inspire Medical Systems (NYSE:INSP) and Hill-Rom (NYSE:HRC) are both mid-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, valuation, earnings and risk.

Risk and Volatility

Inspire Medical Systems has a beta of 1.71, suggesting that its share price is 71% more volatile than the S&P 500. Comparatively, Hill-Rom has a beta of 0.58, suggesting that its share price is 42% less volatile than the S&P 500.

Valuation and Earnings

This table compares Inspire Medical Systems and Hill-Rom's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Inspire Medical Systems$82.05 million72.33$-33,240,000.00($1.40)-156.04
Hill-Rom$2.88 billion2.60$223 million$5.5320.42

Hill-Rom has higher revenue and earnings than Inspire Medical Systems. Inspire Medical Systems is trading at a lower price-to-earnings ratio than Hill-Rom, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings for Inspire Medical Systems and Hill-Rom, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Inspire Medical Systems03802.73
Hill-Rom01602.86

Inspire Medical Systems currently has a consensus target price of $168.5455, suggesting a potential downside of 22.84%. Hill-Rom has a consensus target price of $121.00, suggesting a potential upside of 7.14%. Given Hill-Rom's stronger consensus rating and higher possible upside, analysts clearly believe Hill-Rom is more favorable than Inspire Medical Systems.

Profitability

This table compares Inspire Medical Systems and Hill-Rom's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Inspire Medical Systems-61.07%-32.23%-26.42%
Hill-Rom7.74%22.71%8.01%

Institutional and Insider Ownership

96.3% of Inspire Medical Systems shares are owned by institutional investors. Comparatively, 83.8% of Hill-Rom shares are owned by institutional investors. 6.6% of Inspire Medical Systems shares are owned by company insiders. Comparatively, 0.7% of Hill-Rom shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Hill-Rom beats Inspire Medical Systems on 9 of the 14 factors compared between the two stocks.


Inspire Medical Systems Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Teleflex logo
TFX
Teleflex
1.8$427.09+1.6%$19.97 billion$2.60 billion54.97
Insulet logo
PODD
Insulet
1.4$287.13+0.9%$18.97 billion$738.20 million652.58
Abiomed logo
ABMD
Abiomed
1.4$333.81+1.2%$15.10 billion$840.88 million73.36
NovoCure logo
NVCR
NovoCure
1.5$132.09+0.3%$13.53 billion$351.32 million695.25Analyst Upgrade
Insider Selling
Penumbra logo
PEN
Penumbra
1.5$272.03+0.0%$9.92 billion$547.41 million-1,007.52
Hill-Rom logo
HRC
Hill-Rom
1.8$112.94+1.4%$7.49 billion$2.88 billion34.02
Globus Medical logo
GMED
Globus Medical
1.4$67.00+1.1%$6.69 billion$785.37 million72.83News Coverage
Haemonetics logo
HAE
Haemonetics
1.6$117.06+2.8%$5.95 billion$988.48 million56.55
Integra LifeSciences logo
IART
Integra LifeSciences
1.4$70.12+0.9%$5.92 billion$1.52 billion104.66
Inari Medical logo
NARI
Inari Medical
1.1$113.64+0.2%$5.54 billionN/A0.00Insider Selling
Tandem Diabetes Care logo
TNDM
Tandem Diabetes Care
1.6$87.99+0.0%$5.50 billion$362.30 million-108.63
Nevro logo
NVRO
Nevro
1.2$147.08+0.9%$5.09 billion$390.26 million-54.07
ShockWave Medical logo
SWAV
ShockWave Medical
1.2$137.01+0.7%$4.77 billion$42.93 million-67.83
ICU Medical logo
ICUI
ICU Medical
1.5$204.19+0.1%$4.33 billion$1.27 billion54.02
iRhythm Technologies logo
IRTC
iRhythm Technologies
1.6$132.76+1.3%$3.87 billion$214.55 million-69.51
Glaukos logo
GKOS
Glaukos
0.9$83.13+3.3%$3.81 billion$236.98 million-50.38Analyst Upgrade
Analyst Revision
News Coverage
Cantel Medical logo
CMD
Cantel Medical
1.3$83.76+0.5%$3.54 billion$1.02 billion99.72Insider Selling
NuVasive logo
NUVA
NuVasive
1.1$68.71+1.7%$3.53 billion$1.17 billion-312.32
Merit Medical Systems logo
MMSI
Merit Medical Systems
1.5$61.50+1.5%$3.42 billion$994.85 million-116.04News Coverage
AtriCure logo
ATRC
AtriCure
1.5$65.90+1.0%$3.00 billion$230.81 million-57.30
Axonics Modulation Technologies logo
AXNX
Axonics Modulation Technologies
1.3$60.13+0.2%$2.50 billion$13.82 million-30.68
Inovio Pharmaceuticals logo
INO
Inovio Pharmaceuticals
1.4$8.72+0.9%$1.82 billion$4.11 million-6.41
GenMark Diagnostics logo
GNMK
GenMark Diagnostics
1.5$23.99+0.2%$1.75 billion$88.02 million-58.51
Silk Road Medical logo
SILK
Silk Road Medical
1.1$50.14+0.7%$1.72 billion$63.35 million-41.10
Alphatec logo
ATEC
Alphatec
0.8$17.60+1.3%$1.67 billion$113.43 million-16.00Analyst Report
News Coverage
Luminex logo
LMNX
Luminex
1.8$32.95+2.0%$1.56 billion$334.64 million84.49News Coverage
Pulmonx logo
LUNG
Pulmonx
1.4$43.48+4.7%$1.55 billion$32.60 million0.00Insider Selling
Cardiovascular Systems logo
CSII
Cardiovascular Systems
1.7$36.13+0.8%$1.45 billion$236.54 million-54.74
MiMedx Group logo
MDXG
MiMedx Group
1.7$12.72+5.0%$1.42 billion$299.26 million-13.53
Atrion logo
ATRI
Atrion
1.1$644.00+0.3%$1.18 billion$155.07 million36.28
SI-BONE logo
SIBN
SI-BONE
1.2$33.76+0.5%$1.10 billion$67.30 million-21.10Insider Selling
Tactile Systems Technology logo
TCMD
Tactile Systems Technology
1.2$54.00+0.9%$1.06 billion$189.49 million-120.00News Coverage
LeMaitre Vascular logo
LMAT
LeMaitre Vascular
1.9$51.44+2.0%$1.06 billion$117.23 million55.31
Cerus logo
CERS
Cerus
1.7$6.13+1.0%$1.03 billion$74.65 million-15.72Analyst Upgrade
Analyst Revision
OrthoPediatrics logo
KIDS
OrthoPediatrics
1.5$49.55+0.0%$974.05 million$72.55 million-34.41Analyst Report
AngioDynamics logo
ANGO
AngioDynamics
1.4$23.77+1.7%$906.52 million$264.16 million-5.32
CryoLife logo
CRY
CryoLife
2.0$22.61+0.1%$884.50 million$276.22 million-59.50
Orthofix Medical logo
OFIX
Orthofix Medical
1.2$42.87+1.6%$836.48 million$459.95 million35.73
Surmodics logo
SRDX
Surmodics
1.3$57.14+0.9%$786.02 million$94.86 million714.25
OraSure Technologies logo
OSUR
OraSure Technologies
1.7$10.42+0.3%$749.68 million$154.60 million-45.30
Antares Pharma logo
ATRS
Antares Pharma
1.8$4.10+0.5%$689.46 million$123.86 million68.34Analyst Upgrade
Intersect ENT logo
XENT
Intersect ENT
1.4$20.49+1.7%$676.50 million$109.14 million-10.73News Coverage
SeaSpine logo
SPNE
SeaSpine
1.3$21.94+2.1%$612.85 million$159.08 million-13.14Analyst Report
Analyst Revision
News Coverage
Gap Down
Vapotherm logo
VAPO
Vapotherm
1.5$23.26+0.7%$600.27 million$48.10 million-11.08News Coverage
Anika Therapeutics logo
ANIK
Anika Therapeutics
1.5$39.80+1.7%$570.33 million$114.51 million-84.68News Coverage
Pulse Biosciences logo
PLSE
Pulse Biosciences
1.5$21.81+1.0%$568.96 millionN/A-9.61Analyst Downgrade
News Coverage
PAVmed logo
PAVM
PAVmed
1.2$6.00+1.8%$494.77 millionN/A-7.89
Accuray logo
ARAY
Accuray
2.3$5.21+0.6%$484.00 million$382.93 million37.21
iCAD logo
ICAD
iCAD
1.5$18.55+1.0%$462.23 million$31.34 million-19.53Analyst Upgrade
ClearPoint Neuro logo
CLPT
ClearPoint Neuro
1.4$22.12+1.9%$457.29 million$11.22 million-50.27
This page was last updated on 4/10/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.